Cargando…

Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes

Despite increases in the availability and effectiveness of other therapies, insulin remains an essential treatment for approximately 30 million people with type 2 diabetes worldwide. The development of biosimilars has created the potential for significant health care cost savings and may lead to gre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heller, Simon, Raposo, João Filipe, Tofé, Santiago, Hanif, Wasim, Schroner, Zbynek, Down, Su, Blevins, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2023
Materias:	Feature Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115621/ https://www.ncbi.nlm.nih.gov/pubmed/37092154 http://dx.doi.org/10.2337/cd22-0016

Ejemplares similares

How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?
por: Triplitt, Curtis, et al.
Publicado: (2017)

Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study
por: Pantalone, Kevin M., et al.
Publicado: (2023)

The importance of breaks
por: Sanderson, Susie
Publicado: (2020)

Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin
por: Hinnen, Debbie A.
Publicado: (2015)

Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)
por: Edelman, Steven, et al.
Publicado: (2023)

Survey Reveals Patient and Health Care Provider Experiences and Challenges With the Use of High Doses of Basal Insulin
por: Goldman, Jennifer D., et al.
Publicado: (2023)

Short-Term Outcomes for Veterans Receiving Basal Insulin, Metformin, and a Sulfonylurea Who Are Started on a Third Noninsulin Agent Versus Prandial Insulin
por: Santeusanio, Andrew D., et al.
Publicado: (2018)

Toward structure-based drug design against the epidermal growth factor receptor (EGFR)
por: Haddad, Yazan, et al.
Publicado: (2020)

Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know
por: Skolnik, Neil, et al.
Publicado: (2018)

iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes
por: Hinnen, Debbie, et al.
Publicado: (2018)

Use of Flash Continuous Glucose Monitoring Is Associated With A1C Reduction in People With Type 2 Diabetes Treated With Basal Insulin or Noninsulin Therapy
por: Wright, Eugene E., et al.
Publicado: (2021)

Barriers to the provision of oral health care for people with disabilities
por: Hansen, Charlotte, et al.
Publicado: (2021)

The Future of Biosimilar Insulins
por: Kim, Anne Park, et al.
Publicado: (2016)

Biosimilar insulin concepts
por: Bloomgarden, Zachary T.
Publicado: (2022)

Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications
por: Wysham, Carol H., et al.
Publicado: (2018)

Stigma: A Barrier in Supporting Nurse Well-Being During the Pandemic
por: Weston, Marla J., et al.
Publicado: (2022)

Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States
por: Loughlin, Anita M., et al.
Publicado: (2018)

Barriers to Faculty Pedagogical Change: Lack of Training, Time, Incentives, and…Tensions with Professional Identity?
por: Brownell, Sara E., et al.
Publicado: (2012)

Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice
por: Blonde, Lawrence, et al.
Publicado: (2019)

The First Line of Defense: The Effects of Alcohol on Post-Burn Intestinal Barrier, Immune Cells, and Microbiome
por: Hammer, Adam M., et al.
Publicado: (2015)

Facilitators and Barriers to Smart Insulin Pen Use: A Mixed-Method Study of Multidisciplinary Stakeholders From Diabetes Teams in the United States
por: Ospelt, Emma, et al.
Publicado: (2023)

Introduction of biosimilar insulins in Europe
por: Davies, M., et al.
Publicado: (2017)

Bridging the Blood-Brain Barrier: New Methods Improve the Odds of Getting Drugs to the Brain Cells That Need Them
por: Ferber, Dan
Publicado: (2007)

Architecture and evolution of semantic networks in mathematics texts
por: Christianson, Nicolas H., et al.
Publicado: (2020)

Barriers in Bangladesh
por: Saha, Senjuti, et al.
Publicado: (2018)

Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2021)

Biosimilar insulins: a European perspective
por: DeVries, J H, et al.
Publicado: (2015)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Role of Emerging Insulin Technologies in the Initiation and Intensification of Insulin Therapy for Diabetes in Primary Care
por: Brunton, Stephen A., et al.
Publicado: (2016)

Inactivation of Prefrontal Cortex Attenuates Behavioral Arousal Induced by Stimulation of Basal Forebrain During Sevoflurane Anesthesia
por: Dean, Jon G., et al.
Publicado: (2022)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Insulin Therapy: A Personal Approach
por: Davidson, Mayer B.
Publicado: (2015)

Advances in Insulin Therapy: A Review of New Insulin Glargine 300 Units/mL in the Management of Diabetes
por: White, John R.
Publicado: (2016)

Barriers to Oncology Biosimilars Uptake in the United States
por: Nabhan, Chadi, et al.
Publicado: (2018)

Biosimilar insulins: Informed choice for South Asia
por: Kalra, Sanjay, et al.
Publicado: (2016)

Biosimilar and Follow-on Insulin: The Ins, Outs, and Interchangeability
por: White, John, et al.
Publicado: (2018)

Update on Insulin Therapy for Type 2 Diabetes
por: Donner, Thomas, et al.
Publicado: (2012)

Treatment Approach to Patients With Severe Insulin Resistance
por: Church, Timothy J., et al.
Publicado: (2016)

Nontraditional Considerations With Insulin Needle Length Selection
por: O’Neal, Katherine S., et al.
Publicado: (2015)

Successful Treatment of Type B Insulin Resistance With Rituximab
por: Manikas, Emmanouil-Dimitrios, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_h25oquc3oc3ehjhqc0ktceip86